Spring 2026
Special: CDMO Landscape Europe
Today, 90% of biotechs outsource manufacturing to CDMOs. Outsourcing decisions are no longer straightforward cost-benefit analyses. Geopolitical volatility and unprecedented demand for advanced modalities have made CDMO partnerships existential. Pharma and biotech leaders face fundamentally different pressures, tensions that take center stage at CDMO Live Europe 2026 (19–21 May, Rotterdam).
The European CDMO market is expanding at 7–7.6% CAGR, with valuations clustering around €35–€42 billion in 2025–2026 and forecasts reaching €60–€89 billion by 2034–2035. Germany leads with 30% market share, while France is the fastest-growing market, driven by €1.87 billion in pharmaceutical investment for manufacturing capacity.
In this Special:
- How Europe’s external manufacturing ecosystem is evolving
- The European CDMO Model, Powering Biologics Innovation
- Mitigating regulatory risk with holistic CMC strategies
